RankAlpha logo
Back to Rankings

CERT

CertaraD
Nasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
View Chart
Current thesis
Q2 results were described as in line with expectations; software revenue and bookings grew, guidance was reaffirmed, cost actions imply approximately $13 million of run-rate savings, and the company authorized an additional $50 million share repurchase program [#SEC-8K-2026-08-04].
Posture
Defensive
Lead driver
Value
What changed
6 setup hits (3d) with net bullish as of 2026-10-27.
What can break
AI commercialization and the stated long-term double-digit growth objective remain unproven.
Momentum
93
Value
55
Sentiment
33
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $8.10 · Bull $9.80 · Bear $6.80Analysis 2026-08-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-07 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-27

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions

Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Bullish
Target $9.17
Why
Momentum93 · Δ7d -2.0
Value55 · Δ7d -1.1
Sentiment33 · Δ7d -11.1
So what
Weak posture (Net Bullish). Prioritize risk control and patience.

Confirming evidence

  • • 6 setup hits (3d) with net bullish as of 2026-10-27.
  • • Value remains the lead driver in the composite, 7D delta -1.1.

Contradictions & invalidation

  • • AI commercialization and the stated long-term double-digit growth objective remain unproven.
  • • Profitability remains pressured, with Q2 net loss and adjusted EBITDA weaker year over year.
  • • Growth remains modest, services revenue declined 3%, net loss widened to $6.1 million, and adjusted EBITDA declined 3%.

Catalyst clock

2026-12-31

H2 services recovery against reaffirmed FY2026 outlook

Lead driver: Value · See fundamentals
Momentum
93
8% active weight
Current posture
7d trendSoftening
Δ7d
-2.0
Δ21d
-2.1
Value
55
47% active weight
Current posture
7d trendSoftening
Δ7d
-1.1
Δ21d
-1.6
Sentiment
33
45% active weight
Current posture
7d trendSoftening
Δ7d
-11.1
Δ21d
-10.8
Why this grade

Composite grade D. Momentum 93.4 / Value 55.4 / Sentiment 33.1

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-07. Scenario method

B+
Bull case
25%
Probability
Target price
$9.80
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
Most likely
B
Base case
50%
Probability
Target price
$8.10
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$6.80
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$1.67B
Beta
1.48
Shares Out
152.54M
P/E (TTM)
133.8
P/S (TTM)
3.46
P/FCF (TTM)
15.73
Rev YoY
+1.0%
EPS YoY
-642.6%
Gross Margin
+48.5%
Op Margin
+4.6%
Net Debt
$116.06M
Current Ratio
2.55
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data